aap places mandatory convertible bond 2023/2028 in the amount of EUR 2.5 million – Biotech Investments

aap Implantate AG / Key word(s): Corporate Action

aap places mandatory convertible bond 2023/2028 in the amount of EUR 2.5 million

04-Oct-2023 / 19:58 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

aap Implantate AG (“aap” or the “Company”) today completed the placement of the mandatory convertible bond 2023/2028, which the Company’s Management Board resolved to issue with the approval of the Supervisory Board on September 8, 2023.

The issue met with a positive response from shareholders and new investors of aap in a capital market environment that remains challenging. A total of 2,427,837 bonds with a total nominal value of EUR 2,500,672.56 were placed as part of the public offering and the private placement. The mandatory convertible bond 2023/2028 has thus been subscribed to the extent of around 92 % of the bonds offered.

The mandatory convertible bond 2023/2028 carries an interest rate of 6 % per annum for a term of five years.

The bond is a key component of the refinancing process currently being implemented by aap. The proceeds will be used to secure the company’s financing and will be accompanied by restructuring measures to make the operational trauma business profitable. The measures are to be implemented by the end of the year.

Trading of the mandatory convertible bond 2023/2028 (ISIN: DE000A351ZH9 / WKN: A351ZH) on the Regulated Unofficial Market (Freiverkehr) of the Frankfurt Stock Exchange is expected to commence at the beginning of the term of the mandatory convertible bond on October 6, 2023.

The transaction was accompanied by BankM AG, Frankfurt am Main.

——————————————————-
aap Implantate AG (ISIN DE0005066609) – General Standard/Regulated Market – All German Stock Exchanges –

About aap Implantate AG
aap Implantate AG is a globally active medical technology company based in Berlin, Germany. The company develops, manufactures and markets products for traumatology. In addition to the innovative anatomical plate system LOQTEQ®, the IP-protected portfolio includes a wide range of cannulated screws. In addition, aap Implantate AG has an innovation pipeline with promising development projects such as antibacterial silver coating technology and magnesium-based implants. These technologies address critical problems in traumatology that have not yet been adequately solved. In Germany, aap Implantate AG sells its products directly to hospitals, purchasing groups and group clinics, while at international level it primarily uses a broad network of distributors in around 25 countries. In the USA, the company relies on a hybrid sales strategy through its subsidiary aap Implants Inc. This involves sales both via distribution agents and as part of partnerships with global orthopedic companies. The aap Implantate AG share is listed in the General Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further information, please visit our website at www.aap.de.

Forward-looking statements
This release may contain forward-looking statements based on current expectations, beliefs and projections of the Management Board and currently available information. The forward-looking statements are not guarantees of future performance or results. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in aap’s public reports. Forward-looking statements therefore speak only as of the date they are made. We assume no obligation to update the forward-looking statements made in this release or to conform them to future events or developments.

Contact:
aap Implantate AG; Marek Hahn; Member of the Management Board; Lorenzweg 5; 12099 Berlin
Tel.: 030/750 19 – 178; Fax: 030/750 19 – 290; E-mail: m.hahn@aap.de

End of Inside Information

04-Oct-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

show this

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.

Subscribe

* indicates required